Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit
June 19 2023 - 11:00AM
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage
biotech company developing a new class of custom-built protein
drugs known as DARPin therapeutics, today announced that the
Company will present in a fireside chat at the TD Cowen
Radiopharmaceutical Innovation Summit on Tuesday, June 20,
2023 at 12:00 p.m. ET. Presenting on behalf of Molecular
Partners will be Patrick Amstutz, Chief Executive Officer, and
Daniel Steiner, SVP Research.
A live webcast of the event will be available on
the "News and Events" page in the "Events" section of the Company's
website. A replay of the webcast will be archived on the Company's
website for 1 year following their respective presentation
dates.
About Molecular Partners
AG Molecular Partners AG is a clinical-stage
biotech company developing DARPin (designed ankyrin repeat
protein) therapeutics, a new class of custom-built protein
drugs designed to address challenges current modalities cannot. The
Company has formed partnerships with leading pharmaceutical
companies to advance DARPin therapeutics in the areas of
oncology and virology and has compounds in various stages of
clinical and preclinical development across multiple therapeutic
areas. www.molecularpartners.com Find us on Twitter
- @MolecularPrtnrs
For further details, please
contact:Seth Lewis, Investor
Relationsseth.lewis@molecularpartners.comTel: +1 781 420 2361
Antonio Ligi, CommunicationsZurich-Schlieren,
Switzerlandantonio.ligi@molecularpartners.comTel: +41 79 723 36
81
Molecular Partners (NASDAQ:MOLN)
Historical Stock Chart
From Apr 2024 to May 2024
Molecular Partners (NASDAQ:MOLN)
Historical Stock Chart
From May 2023 to May 2024